Comparison of the two low-grade oncocytic tumour series by Trpkov et al and the present cohort
| Trpkov et al 11 | Akgul et al | |
| Study size | 28 | 23 |
| M/F ratio | 10:18 | 14:9 |
| Median age (range) | 66 (49–78) | 66 (23–84) |
| Procedures | ||
| Partial nephrectomy | 11 (39%) | 15 (65%) |
| Radical nephrectomy | 14 (50%) | 7 (31%) |
| Biopsy | 3 (11%) | 1 (4%) |
| Tumour size (cm) (range) | 3.9 (1.1–13.5) | 4.0 (1.6–10.5) |
| Tumour stage | ||
| pT1a | 17 (68%) | 10 (45%) |
| pT1b | 5 (25%) | 9 (40%) |
| >pT1 | 3 (12%) | 3 (14%) |
| Immunoprofile | ||
| CK7 | 28 (100%) | 23 (100%) |
| CD117 | 7 (2%) | 0 |
| Vimentin | 0 | 8 (35%) |
| CD10 | 3 (11%) | 6 (46%) |
| AMACR | 9 (32%) | 5 (63%) |
| Follow-up (mo) (range) | 21 (1–118) | 30 (2–93) |
| Recurrence | None | None |
| Metastasis | None | None |
AMACR, Alpha-Methylacyl-CoA Racemase; F, female; M, male; mo, month.